<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528357</url>
  </required_header>
  <id_info>
    <org_study_id>201212</org_study_id>
    <secondary_id>2015-000152-14</secondary_id>
    <nct_id>NCT02528357</nct_id>
  </id_info>
  <brief_title>GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)</brief_title>
  <official_title>A Phase I, Open-Label Study of GSK3174998 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Subjects With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first time in human (FTIH), open-label, non-randomized, multicenter study designed&#xD;
      to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and&#xD;
      preliminary clinical activity of GSK3174998 administered intravenously to participants with&#xD;
      selected advanced or recurrent solid tumors. This dose-escalation study will assess the&#xD;
      safety, activity of GSK3174998 as monotherapy (Part 1), in combination with pembrolizumab&#xD;
      (Part 2), and potentially in combination with additional therapies.&#xD;
&#xD;
      The study will be conducted in 2 parts, each part consisting of starting with a&#xD;
      dose-escalation phase followed by a cohort expansion phase. GSK3174998 will first be&#xD;
      evaluated as monotherapy in escalating doses. Once a dose of GSK3174998 has been identified&#xD;
      that is both tolerable and demonstrates pharmacodynamic activity, enrollment of Part 2 may&#xD;
      begin. In Part 2, escalating doses of GSK3174998 will be evaluated with fixed doses of&#xD;
      pembrolizumab.&#xD;
&#xD;
      The maximum duration of treatment with GSK3174998 and pembrolizumab will be approximately 2&#xD;
      years or 35 cycles, whichever comes first. The follow-up period for safety assessments will&#xD;
      be a minimum of 3 months from the date of the last dose. The post-treatment follow-up period&#xD;
      will include disease assessments every 12 weeks until documented progressive disease (PD).&#xD;
      Approximately 141 participants with selected advanced or recurrent solid tumors will be&#xD;
      enrolled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2015</start_date>
  <completion_date type="Actual">April 29, 2020</completion_date>
  <primary_completion_date type="Actual">April 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Any Serious Adverse Event (SAE) and Non-serious Adverse Event (Non-SAE)</measure>
    <time_frame>Up to maximum 39 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With Any SAE and Non-SAE</measure>
    <time_frame>Up to maximum 105 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With Any SAE and Non-SAE</measure>
    <time_frame>Up to maximum 33 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>28 days</time_frame>
    <description>An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of &gt;7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of &gt;=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With DLTs</measure>
    <time_frame>28 days</time_frame>
    <description>An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of &gt;7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of &gt;=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With DLTs</measure>
    <time_frame>28 days</time_frame>
    <description>An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of &gt;7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of &gt;=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Any Adverse Event Leading to Withdrawal (AELD) From the Study</measure>
    <time_frame>Up to maximum 39 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study</measure>
    <time_frame>Up to maximum 105 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study</measure>
    <time_frame>Up to maximum 33 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Dose Reductions or Delay</measure>
    <time_frame>Up to maximum 39 weeks</time_frame>
    <description>Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With Dose Reductions or Delay</measure>
    <time_frame>Up to maximum 105 weeks</time_frame>
    <description>Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With Dose Reductions or Delay</measure>
    <time_frame>Up to maximum 33 weeks</time_frame>
    <description>Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters</measure>
    <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), leukocyte count (leuko.), lymphocyte count (Lymph.), neutrophil count (Neutro.) and platelet count (PC). The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters</measure>
    <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following hematology parameters: Hb, leuko., Lymph., Neutro. and PC. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters</measure>
    <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following hematology parameters: Hb, leuko., Lymph., Neutro. and PC. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters</measure>
    <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following liver function laboratory parameters: alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST) and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters</measure>
    <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following liver function laboratory parameters: ALT, ALP, AST and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters</measure>
    <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following liver function laboratory parameters: ALT, ALP, AST and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Any Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
    <description>SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: &lt;120 millimeter mercury (mmHg); Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: &gt;=160 mmHg. For DBP: Grade 0: &lt;80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: &gt;=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With Any Grade Change From Baseline in SBP and DBP</measure>
    <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
    <description>SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: &lt;120 mmHg; Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: &gt;=160 mmHg. For DBP: Grade 0: &lt;80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: &gt;=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With Any Grade Change From Baseline in SBP and DBP</measure>
    <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
    <description>SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: &lt;120 mmHg; Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: &gt;=160 mmHg. For DBP: Grade 0: &lt;80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: &gt;=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Change From Baseline in Heart Rate (HR)</measure>
    <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
    <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: &lt;60 beats per minute [bpm]', normal HR: 60 to 100 bpm and high HR: &gt;100 bpm. If values were unchanged (example: increase to &gt;100 bpm to increase to &gt;100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With Worst Case Change From Baseline in HR</measure>
    <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
    <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: &lt;60 bpm', normal HR: 60 to 100 bpm and high HR: &gt;100 bpm. If values were unchanged (example: increase to &gt;100 bpm to increase to &gt;100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With Worst Case Change From Baseline in HR</measure>
    <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
    <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: &lt;60 bpm', normal HR: 60 to 100 bpm and high HR: &gt;100 bpm. If values were unchanged (example: increase to &gt;100 bpm to increase to &gt;100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
    <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: &lt;=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: &gt;=38 degrees Celsius. If values were unchanged (example: increase to &gt;=38 degrees Celsius to increase to &gt;=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With Worst Case Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
    <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: &lt;=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: &gt;=38 degrees Celsius. If values were unchanged (example: increase to &gt;=38 degrees Celsius to increase to &gt;=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With Worst Case Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
    <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: &lt;=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: &gt;=38 degrees Celsius. If values were unchanged (example: increase to &gt;=38 degrees Celsius to increase to &gt;=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>Up to maximum 39 weeks</time_frame>
    <description>A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2A: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings</measure>
    <time_frame>Up to maximum 105 weeks</time_frame>
    <description>A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2B: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings</measure>
    <time_frame>Up to maximum 33 weeks</time_frame>
    <description>A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Objective Response Rate (ORR)</measure>
    <time_frame>Up to maximum 39 weeks</time_frame>
    <description>ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or a partial response (PR) as the Best Overall Response (BOR), as assessed by the investigator per Response Evaluation Criteria In Solid Tumors (RECIST) Version (v) 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30 percent (%) decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Objective Response Rate (ORR)</measure>
    <time_frame>Up to maximum 105 weeks</time_frame>
    <description>ORR is defined as the percentage of participants achieving a confirmed CR or PR as the BOR, as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: Objective Response Rate (ORR)</measure>
    <time_frame>Up to maximum 33 weeks</time_frame>
    <description>ORR is defined as the percentage of participants achieving a confirmed CR or PR as the BOR, as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Disease Control Rate (DCR)</measure>
    <time_frame>Up to maximum 39 weeks</time_frame>
    <description>DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus stable disease (SD) &gt;=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Disease Control Rate (DCR)</measure>
    <time_frame>Up to maximum 105 weeks</time_frame>
    <description>DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus SD &gt;=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: Disease Control Rate (DCR)</measure>
    <time_frame>Up to maximum 33 weeks</time_frame>
    <description>DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus SD &gt;=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points</measure>
    <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion</time_frame>
    <description>Blood samples for pharmacokinetic (PK) analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points</measure>
    <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion</time_frame>
    <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points</measure>
    <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion</time_frame>
    <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK3174998</measure>
    <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: AUC(0-tau) of GSK3174998</measure>
    <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: AUC(0-tau) of GSK3174998</measure>
    <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998</measure>
    <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Cmax and Cmin of GSK3174998</measure>
    <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: Cmax and Cmin of GSK3174998</measure>
    <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points</measure>
    <time_frame>Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22, 64, 106</time_frame>
    <description>Blood samples for PK analysis of pembrolizumab were collected on Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion (EOPI); anytime on Days 8,15; Pre-dose on Days 22, 64, 106.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points</measure>
    <time_frame>Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22, 64, 106</time_frame>
    <description>Blood samples for PK analysis of pembrolizumab were collected on Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22, 64, 106.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: AUC(0-tau) of Pembrolizumab</measure>
    <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: AUC(0-tau) of Pembrolizumab</measure>
    <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Cmax of Pembrolizumab</measure>
    <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: Cmax of Pembrolizumab</measure>
    <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Cmin of Pembrolizumab</measure>
    <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: Cmin of Pembrolizumab</measure>
    <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days)</time_frame>
    <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Positive Antidrug Antibodies (ADAs) Against GSK3174998</measure>
    <time_frame>Up to maximum 39 weeks</time_frame>
    <description>Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point determined during assay validation. Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Number of Participants With Positive ADAs Against GSK3174998</measure>
    <time_frame>Up to maximum 105 weeks</time_frame>
    <description>Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: Number of Participants With Positive ADAs Against GSK3174998</measure>
    <time_frame>Up to maximum 33 weeks</time_frame>
    <description>Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Number of Participants With Positive ADAs Against Pembrolizumab</measure>
    <time_frame>Up to maximum 105 weeks</time_frame>
    <description>Serum samples were collected for the determination of anti-pembrolizumab antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a pembrolizumab bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with pembrolizumab that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-pembrolizumab antibodies results at any visit during the study have been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2B: Number of Participants With Positive ADAs Against Pembrolizumab</measure>
    <time_frame>Up to maximum 33 weeks</time_frame>
    <description>Serum samples were planned to be collected for the determination of anti-pembrolizumab antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part 1A: GSK3174998 Monotherapy- Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3174998 intravenously (IV) (dose range 0.003 to 10.0 milligram per kilogram [mg/kg]) every 3 weeks (Q3W) for up to 2 years or 35 cycles, whichever comes first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: GSK3174998+ pembrolizumab - Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3174998 IV (dose range 0.003 to 10.0 mg/kg) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for up to 2 years or 35 cycles, whichever comes first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B: GSK3174998+ pembrolizumab - Cohort expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation of part 2A) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for 2 years or 35 cycles, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3174998</intervention_name>
    <description>Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to &lt;=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W</description>
    <arm_group_label>Part 1A: GSK3174998 Monotherapy- Dose escalation</arm_group_label>
    <arm_group_label>Part 2A: GSK3174998+ pembrolizumab - Dose escalation</arm_group_label>
    <arm_group_label>Part 2B: GSK3174998+ pembrolizumab - Cohort expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W</description>
    <arm_group_label>Part 2A: GSK3174998+ pembrolizumab - Dose escalation</arm_group_label>
    <arm_group_label>Part 2B: GSK3174998+ pembrolizumab - Cohort expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide signed, written informed consent.&#xD;
&#xD;
          -  Male and female participants, age &gt;=18 years (at the time consent is obtained).&#xD;
&#xD;
          -  Histological documentation of locally advanced, recurrent or metastatic solid&#xD;
             malignancy that has progressed after standard therapy appropriate for the specific&#xD;
             tumor type, or for which standard therapy has proven to be ineffective, intolerable,&#xD;
             or is considered inappropriate. Participants should not have received more than 5&#xD;
             prior lines of therapy for advanced disease including both standards of care and&#xD;
             investigational therapies. Participants whose cancers harbor molecular alterations for&#xD;
             which targeted therapy is standard of care should have received health authority&#xD;
             approved appropriate targeted therapy for their tumor types before enrollment.&#xD;
&#xD;
          -  Participants with the following solid tumors are eligible for screening: Non-small&#xD;
             cell lung cancer (NSCLC), Squamous cell carcinoma of the head and neck (SCCHN), Renal&#xD;
             cell carcinoma (RCC), melanoma, bladder, Soft Tissue Sarcoma (STS), Triple-negative&#xD;
             breast cancer (TNBC), and Colorectal carcinoma displaying high microsatellite&#xD;
             instability (MSI CRC). In Part 2B (Cohort Expansion), specific subgroups of the above&#xD;
             solid tumors will be studied. These subgroups may be defined by specific lines of&#xD;
             treatment, types of prior treatment, histological subtypes, and may be enriched for&#xD;
             selected biomarkers or participant characteristics. Populations to be studied in&#xD;
             Amendment 3 include but are not limited to the following. Enrolment of additional&#xD;
             populations will be communicated in writing: Participants with dedifferentiated&#xD;
             liposarcoma who have not received prior treatment with a Programmed death ligand 1&#xD;
             (PD-L1) inhibitor; Participants with melanoma who have received a prior PD-L1&#xD;
             inhibitor, had a CR, PR or SD and subsequently progressed while on PD-L1 therapy.&#xD;
             Participants who have received prior treatment with a PD-L1 inhibitor must have&#xD;
             documented disease progression as defined by meeting all of the following criteria:&#xD;
             Has received at least 2 doses of an approved PD-L1 inhibitor; has demonstrated disease&#xD;
             progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             version 1.1. The initial evidence of disease progression is to be confirmed by a&#xD;
             second assessment no less than four weeks from the date of the first documented PD ,&#xD;
             in the absence of rapid clinical progression; Progressive disease has been documented&#xD;
             within 18 weeks from the last dose of the PD-L1 inhibitor.&#xD;
&#xD;
          -  In Parts 1A and 2A, a biopsy of the tumor tissue obtained at anytime from the initial&#xD;
             diagnosis to study entry. Although a fresh biopsy obtained during screening is&#xD;
             preferred, archival tumor specimen is acceptable if it is not feasible to obtain a&#xD;
             fresh biopsy.&#xD;
&#xD;
        Participants enrolled in Part 1A or Part 2A Pharmacodynamic Cohorts or in Part 2B of the&#xD;
        study must provide a fresh biopsy of a tumor lesion not previously irradiated during the&#xD;
        screening period and must agree to provide at least one additional on-treatment biopsy. In&#xD;
        addition, an archived tumor tissue should be submitted for Participants in Part 2B, if&#xD;
        available. The criterion for collection of fresh biopsies may be waived once&#xD;
        GlaxoSmithKline (GSK)has determined an appropriate number of viable tissue samples have&#xD;
        been analyzed For Part 1B and Part 2B, any archival tumor specimen must have been obtained&#xD;
        within 3 months of starting study drug.&#xD;
&#xD;
          -  Measurable disease as per RECIST v1.1&#xD;
&#xD;
          -  Palpable lesions that are not measurable by radiologic or photographic evaluations may&#xD;
             not be utilized as the only measurable lesion.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Adequate organ function as defined by System Laboratory Values; Hematologic (Absolute&#xD;
             neutrophil count [ANC] &gt;=1.5x10^9/ liter [L], Lymphocyte count &gt;=800/cubic millimeter&#xD;
             [mm^3], Hemoglobin &gt;=9 grams/deciliter [g/dL], Platelets &gt;=100x10^9/L), Hepatic (Total&#xD;
             bilirubin &lt;=1.5x upper limit of normal [ULN] [For participants with Gilbert's&#xD;
             Syndrome, only if direct bilirubin &lt;=35 percent (%), &lt;=3.0xULN], for Part 1A and 2A:&#xD;
             alanine aminotransferase [ALT] &lt;=1.5xULN), Part 2B: ALT &lt;=2.5xULN; Renal (Serum&#xD;
             Creatinine &lt;=1.5xULN OR Calculated creatinine clearance [CrCl &gt;50 mL/min ) and&#xD;
             Endocrine (Thyroid stimulating hormone [TSH]) within normal limits. If TSH is not&#xD;
             within normal limits at baseline, the participant may still be eligible if total&#xD;
             triiodothyronine (T3) or free T3 and free thyroxine (T4) are within the normal limits.&#xD;
&#xD;
          -  QT duration corrected for heart rate by Fridericia's formula (QTcF) &lt;450 milliseconds&#xD;
             (msec) or &lt;480 msec for participants with bundle branch block.&#xD;
&#xD;
          -  In France, a participant will be eligible for inclusion in this study only if either&#xD;
             affiliated to or a beneficiary of a social security category.&#xD;
&#xD;
          -  Female participant: is eligible to participate if she is not pregnant (as confirmed by&#xD;
             a negative serum beta-human chorionic gonadotrophin [beta-hCG] test), not lactating,&#xD;
             and at least one of the following conditions applies: Non-reproductive potential&#xD;
             defined as: Pre-menopausal females with one of the following: Documented tubal&#xD;
             ligation; Documented hysteroscopic tubal occlusion procedure with follow-up&#xD;
             confirmation of bilateral tubal occlusion ; Hysterectomy; Documented Bilateral&#xD;
             Oophorectomy.&#xD;
&#xD;
        Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a&#xD;
        blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels&#xD;
        consistent with menopause). Females on hormone replacement therapy (HRT) and whose&#xD;
        menopausal status is in doubt will be required to use one of the highly effective&#xD;
        contraception methods if they wish to continue their HRT during the study. Otherwise, they&#xD;
        must discontinue HRT to allow confirmation of post-menopausal status prior to study&#xD;
        enrolment.&#xD;
&#xD;
          -  Reproductive potential and agrees to follow one of the options listed below in the GSK&#xD;
             Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of&#xD;
             Reproductive Potential (FRP) requirements from 30 days prior to the first dose of&#xD;
             study medication and until 120 days after the last dose of study medication and&#xD;
             completion of the follow-up visit. GSK Modified List of Highly Effective Methods for&#xD;
             Avoiding Pregnancy in Females of Reproductive Potential (FRP).&#xD;
&#xD;
        This list does not apply to FRP with same sex partners, when this is their preferred and&#xD;
        usual lifestyle or for participants who are and will continue to be abstinent from&#xD;
        penile-vaginal intercourse on a long term and persistent basis: Contraceptive subdermal&#xD;
        implant with a &lt;1% rate of failure per year, as stated in the product label; Intrauterine&#xD;
        device or intrauterine system with a &lt;1% rate of failure per year, as stated in the product&#xD;
        label; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen;&#xD;
        Contraceptive vaginal ring; Percutaneous contraceptive patches; Male partner sterilization&#xD;
        with documentation of azoospermia prior to the female participant's entry into the study,&#xD;
        and this male is the sole partner for that participant. These allowed methods of&#xD;
        contraception are only effective when used consistently, correctly and in accordance with&#xD;
        the product label. The investigator is responsible for ensuring that participants&#xD;
        understand how to properly use these methods of contraception.&#xD;
&#xD;
          -  Male Participants with female partners of child bearing potential must comply with the&#xD;
             following contraception requirements from the time of first dose of study medication&#xD;
             until 120 days after the last dose of study medication: Vasectomy with documentation&#xD;
             of azoospermia; Male condom plus partner use of one of the contraceptive options&#xD;
             below; Contraceptive subdermal implant with a &lt;1% rate of failure per year, as stated&#xD;
             in the product label; Intrauterine device or intrauterine system with a &lt;1% rate of&#xD;
             failure per year, as stated in the product label; Oral Contraceptive, either combined&#xD;
             or progestogen alone Injectable progestogen; Contraceptive vaginal ring; Percutaneous&#xD;
             contraceptive patches.&#xD;
&#xD;
        These allowed methods of contraception are only effective when used consistently, correctly&#xD;
        and in accordance with the product label. The investigator is responsible for ensuring that&#xD;
        participants understand how to properly use these methods of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with the following agents (from last dose of prior treatment to first&#xD;
             dose of GSK3174998): Tumor necrosis factor receptor (TNFR) agonists, including OX40,&#xD;
             CD27, CD137 (4-1BB), CD357 (GITR): at any time; Checkpoint inhibitors, including&#xD;
             Programmed death receptor-1 (PD-1),&#xD;
&#xD;
             1, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors: within 4&#xD;
             weeks; other anticancer therapy, including chemotherapy, targeted therapy, and&#xD;
             biological therapy: within 4 weeks or 5 half lives of the drug, whichever is shorter.&#xD;
             Prior radiation therapy is permissible if at least one unirradiated measurable lesion&#xD;
             is available for assessment via RECIST version 1.1. A wash out of at least two weeks&#xD;
             before start of study drug for palliative radiation to the extremities for osseous&#xD;
             bone metastases and 4 weeks for radiation to the chest, brain, or visceral organs is&#xD;
             required; Investigational therapy: if the participant has participated in a clinical&#xD;
             trial and has received an investigational product: within 30 days or 5 half-lives of&#xD;
             the investigational product (whichever is shorter). At least 14 days must have passed&#xD;
             between the last dose of prior investigational agent and the first dose of study drug.&#xD;
&#xD;
          -  Prior allogeneic or autologous bone marrow transplantation or other solid organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Toxicity from previous treatment: Participants with &gt;=Grade 3 toxicity related to&#xD;
             prior immunotherapy leading to study treatment discontinuation are not eligible;&#xD;
             participants whose toxicity related to prior treatment has not resolved to &lt;=Grade 1&#xD;
             (except alopecia, hearing loss, grade &lt;=2 neuropathy or endocrinopathy managed with&#xD;
             replacement therapy) are not eligible.&#xD;
&#xD;
          -  Malignancy other than disease under study, except as noted below: any other malignancy&#xD;
             from which the participant has been disease-free for more than 2 years and, in the&#xD;
             opinion of the principal investigators and GSK Medical Monitor, will not affect the&#xD;
             evaluation of the effects of this clinical trial treatment on currently targeted&#xD;
             malignancy, can be included in this clinical trial.&#xD;
&#xD;
          -  Central nervous system (CNS) metastases, with the following exception: Participants&#xD;
             who have previously-treated CNS metastases, are asymptomatic, and have had no&#xD;
             requirement for steroids for 2 weeks prior to first dose of study drug.&#xD;
&#xD;
          -  Has received transfusion of blood products (including platelets or red blood cells) or&#xD;
             administration of colony stimulating factors (including granulocyte colony stimulating&#xD;
             factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GMCSF], recombinant&#xD;
             erythropoietin) within 2 weeks before the first dose of study drug.&#xD;
&#xD;
          -  Major surgery &lt;=4 weeks before the first dose of study treatment. Participants must&#xD;
             have also fully recovered from any surgery (major or minor) and/or its complications&#xD;
             before initiating study treatment.&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment within the last 2 years&#xD;
             (that is with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (example [e.g.], thyroxine or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Concurrent medical condition requiring the use of systemic immunosuppressive&#xD;
             medications within 28 days before the first dose of study treatment. Physiologic doses&#xD;
             of corticosteroids for treatment of endocrinopathies or steroids with minimal systemic&#xD;
             absorption, including topical, inhaled, or intranasal corticosteroids may be continued&#xD;
             if the participant is on a stable dose.&#xD;
&#xD;
          -  Active infection, known human immunodeficiency virus infection, or positive test for&#xD;
             hepatitis B surface antigen or hepatitis C.&#xD;
&#xD;
          -  Current active liver or biliary disease (with the exception of Gilbert's syndrome or&#xD;
             asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease&#xD;
             per investigator assessment).&#xD;
&#xD;
          -  Known, current drug or alcohol abuse.&#xD;
&#xD;
          -  Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel&#xD;
             disease, intra-abdominal abscess, or gastrointestinal obstruction.&#xD;
&#xD;
          -  Receipt of any live vaccine within 4 weeks.&#xD;
&#xD;
          -  Recent history of allergen desensitization therapy within 4 weeks of starting study&#xD;
             Treatment.&#xD;
&#xD;
          -  History of severe hypersensitivity to other mAbs.&#xD;
&#xD;
          -  History or evidence of cardiovascular risk including any of the following: Recent&#xD;
             (within the past 6 months) history of serious uncontrolled cardiac arrhythmia or&#xD;
             clinically significant ECG abnormalities including second degree (Type II) or third&#xD;
             degree atrioventricular block; Documented cardiomyopathy, myocardial infarction, acute&#xD;
             coronary syndromes (including unstable angina pectoris), coronary angioplasty,&#xD;
             stenting, or bypass grafting within the past 6 months before enrollment; documented&#xD;
             congestive heart failure (Class II, III, or IV) as defined by the New York Heart&#xD;
             Association functional classification system; recent (within the past 6 months)&#xD;
             history of symptomatic pericarditis Current or history of idiopathic pulmonary&#xD;
             fibrosis, interstitial lung disease, or organizing pneumonia.&#xD;
&#xD;
          -  History of (non-infectious) pneumonitis that required steroids or current pneumonitis.&#xD;
&#xD;
          -  Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural&#xD;
             effusions.&#xD;
&#xD;
          -  Any serious and/or unstable pre-existing medical, psychiatric disorder, or other&#xD;
             condition that could interfere with the participant's safety, obtaining informed&#xD;
             consent, or compliance to the study procedures.&#xD;
&#xD;
          -  Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or&#xD;
             child) who is investigational site or sponsor staff directly involved with this trial,&#xD;
             unless prospective Institutional Review Board (IRB) approval (by chair or designee) is&#xD;
             given allowing exception to this criterion for a specific participant.&#xD;
&#xD;
          -  History of severe hypersensitivity (&gt;=Grade 3) to pembrolizumab and/or any of its&#xD;
             excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <results_first_submitted>April 26, 2021</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK3174998</keyword>
  <keyword>Non-small Cell Lung Cancer (NSCLC)</keyword>
  <keyword>OX40</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Monoclonal Antibody (mAb)</keyword>
  <keyword>Selected Advanced Solid Tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02528357/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02528357/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a 2 part study conducted across 4 countries. Part 1 was dose-escalation study to evaluate GSK3174998 monotherapy. Part 2 included dose-escalation cohorts of GSK3174998+pembrolizumab combination therapy (Comb. Th.) (Part 2A) and dose-expansion (Expan.) disease specific cohorts (Coh.) of GSK3174998 + pembrolizumab (Part 2B).</recruitment_details>
      <pre_assignment_details>A total of 141 participants were enrolled in the study: 45 participants in Part 1 and 96 participants in Part 2 (74 in Part 2A+ 22 in Part 2B).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: GSK3174998 0.003 mg/kg</title>
          <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: GSK3174998 0.01 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: GSK3174998 0.03 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1: GSK3174998 0.1 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 1: GSK3174998 0.3 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 1: GSK3174998 1.0 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="P7">
          <title>Part 1: GSK3174998 3.0 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="P8">
          <title>Part 1: GSK3174998 10.0 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="P9">
          <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="P10">
          <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="P11">
          <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="P12">
          <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="P13">
          <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="P14">
          <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="P15">
          <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="P16">
          <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="P17">
          <title>Part 2B: Melanoma Cohort</title>
          <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
        </group>
        <group group_id="P18">
          <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
          <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
        </group>
        <group group_id="P19">
          <title>Part 2B: NSCLC Cohort</title>
          <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part1:Monotherapy(Up to Maximum 39weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Follow-up assessments removed (Protocol Amendment 4)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part2A:Comb. Th. (Up to Maximum 105wks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="10"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="14"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="9"/>
                <participants group_id="P13" count="9"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Investigator site closed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Follow-up assessments removed (Protocol Amendment 4)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part2B:Expan. Coh.(Up to Maximum 33 Wks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="9"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="4"/>
                <participants group_id="P19" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="4"/>
                <participants group_id="P19" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Follow-up assessments removed (Protocol Amendment 4)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="4"/>
                <participants group_id="P19" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: GSK3174998 0.003 mg/kg</title>
          <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: GSK3174998 0.01 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1: GSK3174998 0.03 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1: GSK3174998 0.1 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 1: GSK3174998 0.3 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 1: GSK3174998 1.0 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="B7">
          <title>Part 1: GSK3174998 3.0 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="B8">
          <title>Part 1: GSK3174998 10.0 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="B9">
          <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="B10">
          <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="B11">
          <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="B12">
          <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="B13">
          <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="B14">
          <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="B15">
          <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="B16">
          <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="B17">
          <title>Part 2B: Melanoma Cohort</title>
          <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
        </group>
        <group group_id="B18">
          <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
          <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
        </group>
        <group group_id="B19">
          <title>Part 2B: NSCLC Cohort</title>
          <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
        </group>
        <group group_id="B20">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="7"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="5"/>
            <count group_id="B10" value="5"/>
            <count group_id="B11" value="10"/>
            <count group_id="B12" value="12"/>
            <count group_id="B13" value="14"/>
            <count group_id="B14" value="12"/>
            <count group_id="B15" value="12"/>
            <count group_id="B16" value="4"/>
            <count group_id="B17" value="9"/>
            <count group_id="B18" value="8"/>
            <count group_id="B19" value="5"/>
            <count group_id="B20" value="141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18 to 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65 to 84 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="3"/>
                    <measurement group_id="B20" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=85 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="4"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="4"/>
                    <measurement group_id="B19" value="4"/>
                    <measurement group_id="B20" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>African American/African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - Central/South Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - South East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>White - Arabic/North African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>White - White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="10"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="12"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="10"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="9"/>
                    <measurement group_id="B18" value="6"/>
                    <measurement group_id="B19" value="4"/>
                    <measurement group_id="B20" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not reported due to participant's confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Any Serious Adverse Event (SAE) and Non-serious Adverse Event (Non-SAE)</title>
        <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
        <time_frame>Up to maximum 39 weeks</time_frame>
        <population>All Treated Population consisted of all participants who received at least one dose of GSK3174998.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Any Serious Adverse Event (SAE) and Non-serious Adverse Event (Non-SAE)</title>
          <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
          <population>All Treated Population consisted of all participants who received at least one dose of GSK3174998.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With Any SAE and Non-SAE</title>
        <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
        <time_frame>Up to maximum 105 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Any SAE and Non-SAE</title>
          <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With Any SAE and Non-SAE</title>
        <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
        <time_frame>Up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Any SAE and Non-SAE</title>
          <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)</title>
        <description>An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of &gt;7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of &gt;=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.</description>
        <time_frame>28 days</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)</title>
          <description>An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of &gt;7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of &gt;=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With DLTs</title>
        <description>An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of &gt;7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of &gt;=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.</description>
        <time_frame>28 days</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With DLTs</title>
          <description>An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of &gt;7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of &gt;=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With DLTs</title>
        <description>An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of &gt;7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of &gt;=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.</description>
        <time_frame>28 days</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With DLTs</title>
          <description>An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of &gt;7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of &gt;=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Any Adverse Event Leading to Withdrawal (AELD) From the Study</title>
        <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.</description>
        <time_frame>Up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Any Adverse Event Leading to Withdrawal (AELD) From the Study</title>
          <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study</title>
        <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.</description>
        <time_frame>Up to maximum 105 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study</title>
          <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study</title>
        <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.</description>
        <time_frame>Up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study</title>
          <description>An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Dose Reductions or Delay</title>
        <description>Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.</description>
        <time_frame>Up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Dose Reductions or Delay</title>
          <description>Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With Dose Reductions or Delay</title>
        <description>Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.</description>
        <time_frame>Up to maximum 105 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Dose Reductions or Delay</title>
          <description>Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With Dose Reductions or Delay</title>
        <description>Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.</description>
        <time_frame>Up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Dose Reductions or Delay</title>
          <description>Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters</title>
        <description>Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), leukocyte count (leuko.), lymphocyte count (Lymph.), neutrophil count (Neutro.) and platelet count (PC). The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
        <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters</title>
          <description>Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), leukocyte count (leuko.), lymphocyte count (Lymph.), neutrophil count (Neutro.) and platelet count (PC). The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hb decreased (anemia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leuko. increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leuko. decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph. decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph. increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutro. decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters</title>
        <description>Blood samples were collected for the analysis of following hematology parameters: Hb, leuko., Lymph., Neutro. and PC. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
        <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters</title>
          <description>Blood samples were collected for the analysis of following hematology parameters: Hb, leuko., Lymph., Neutro. and PC. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hb decreased (anemia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leuko. increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leuko. decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph. decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph. increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutro. decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters</title>
        <description>Blood samples were collected for the analysis of following hematology parameters: Hb, leuko., Lymph., Neutro. and PC. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
        <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters</title>
          <description>Blood samples were collected for the analysis of following hematology parameters: Hb, leuko., Lymph., Neutro. and PC. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hb decreased (anemia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leuko. increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leuko. decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph. decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph. increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutro. decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters</title>
        <description>Blood samples were collected for the analysis of following liver function laboratory parameters: alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST) and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
        <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters</title>
          <description>Blood samples were collected for the analysis of following liver function laboratory parameters: alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST) and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters</title>
        <description>Blood samples were collected for the analysis of following liver function laboratory parameters: ALT, ALP, AST and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
        <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters</title>
          <description>Blood samples were collected for the analysis of following liver function laboratory parameters: ALT, ALP, AST and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters</title>
        <description>Blood samples were collected for the analysis of following liver function laboratory parameters: ALT, ALP, AST and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
        <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters</title>
          <description>Blood samples were collected for the analysis of following liver function laboratory parameters: ALT, ALP, AST and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Any Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: &lt;120 millimeter mercury (mmHg); Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: &gt;=160 mmHg. For DBP: Grade 0: &lt;80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: &gt;=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
        <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Any Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: &lt;120 millimeter mercury (mmHg); Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: &gt;=160 mmHg. For DBP: Grade 0: &lt;80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: &gt;=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With Any Grade Change From Baseline in SBP and DBP</title>
        <description>SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: &lt;120 mmHg; Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: &gt;=160 mmHg. For DBP: Grade 0: &lt;80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: &gt;=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
        <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Any Grade Change From Baseline in SBP and DBP</title>
          <description>SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: &lt;120 mmHg; Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: &gt;=160 mmHg. For DBP: Grade 0: &lt;80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: &gt;=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With Any Grade Change From Baseline in SBP and DBP</title>
        <description>SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: &lt;120 mmHg; Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: &gt;=160 mmHg. For DBP: Grade 0: &lt;80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: &gt;=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
        <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Any Grade Change From Baseline in SBP and DBP</title>
          <description>SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: &lt;120 mmHg; Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: &gt;=160 mmHg. For DBP: Grade 0: &lt;80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: &gt;=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst Case Change From Baseline in Heart Rate (HR)</title>
        <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: &lt;60 beats per minute [bpm]', normal HR: 60 to 100 bpm and high HR: &gt;100 bpm. If values were unchanged (example: increase to &gt;100 bpm to increase to &gt;100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
        <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Change From Baseline in Heart Rate (HR)</title>
          <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: &lt;60 beats per minute [bpm]', normal HR: 60 to 100 bpm and high HR: &gt;100 bpm. If values were unchanged (example: increase to &gt;100 bpm to increase to &gt;100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease to low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase to high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With Worst Case Change From Baseline in HR</title>
        <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: &lt;60 bpm', normal HR: 60 to 100 bpm and high HR: &gt;100 bpm. If values were unchanged (example: increase to &gt;100 bpm to increase to &gt;100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
        <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Worst Case Change From Baseline in HR</title>
          <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: &lt;60 bpm', normal HR: 60 to 100 bpm and high HR: &gt;100 bpm. If values were unchanged (example: increase to &gt;100 bpm to increase to &gt;100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease to low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase to high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With Worst Case Change From Baseline in HR</title>
        <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: &lt;60 bpm', normal HR: 60 to 100 bpm and high HR: &gt;100 bpm. If values were unchanged (example: increase to &gt;100 bpm to increase to &gt;100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
        <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Worst Case Change From Baseline in HR</title>
          <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: &lt;60 bpm', normal HR: 60 to 100 bpm and high HR: &gt;100 bpm. If values were unchanged (example: increase to &gt;100 bpm to increase to &gt;100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease to low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase to high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst Case Change From Baseline in Body Temperature</title>
        <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: &lt;=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: &gt;=38 degrees Celsius. If values were unchanged (example: increase to &gt;=38 degrees Celsius to increase to &gt;=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
        <time_frame>Baseline (Day 1) and up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Change From Baseline in Body Temperature</title>
          <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: &lt;=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: &gt;=38 degrees Celsius. If values were unchanged (example: increase to &gt;=38 degrees Celsius to increase to &gt;=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease to low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase to high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With Worst Case Change From Baseline in Body Temperature</title>
        <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: &lt;=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: &gt;=38 degrees Celsius. If values were unchanged (example: increase to &gt;=38 degrees Celsius to increase to &gt;=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
        <time_frame>Baseline (Day 1) and up to maximum 105 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Worst Case Change From Baseline in Body Temperature</title>
          <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: &lt;=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: &gt;=38 degrees Celsius. If values were unchanged (example: increase to &gt;=38 degrees Celsius to increase to &gt;=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease to low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase to high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With Worst Case Change From Baseline in Body Temperature</title>
        <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: &lt;=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: &gt;=38 degrees Celsius. If values were unchanged (example: increase to &gt;=38 degrees Celsius to increase to &gt;=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
        <time_frame>Baseline (Day 1) and up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Worst Case Change From Baseline in Body Temperature</title>
          <description>Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: &lt;=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: &gt;=38 degrees Celsius. If values were unchanged (example: increase to &gt;=38 degrees Celsius to increase to &gt;=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease to low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase to high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant Electrocardiogram (ECG) Findings</title>
        <description>A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.</description>
        <time_frame>Up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant Electrocardiogram (ECG) Findings</title>
          <description>A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2A: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings</title>
        <description>A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.</description>
        <time_frame>Up to maximum 105 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings</title>
          <description>A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.</description>
          <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2B: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings</title>
        <description>A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.</description>
        <time_frame>Up to maximum 33 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings</title>
          <description>A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.</description>
          <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Objective Response Rate (ORR)</title>
        <description>ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or a partial response (PR) as the Best Overall Response (BOR), as assessed by the investigator per Response Evaluation Criteria In Solid Tumors (RECIST) Version (v) 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30 percent (%) decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.</description>
        <time_frame>Up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Objective Response Rate (ORR)</title>
          <description>ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or a partial response (PR) as the Best Overall Response (BOR), as assessed by the investigator per Response Evaluation Criteria In Solid Tumors (RECIST) Version (v) 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30 percent (%) decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.</description>
          <population>All Treated Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: Objective Response Rate (ORR)</title>
        <description>ORR is defined as the percentage of participants achieving a confirmed CR or PR as the BOR, as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.</description>
        <time_frame>Up to maximum 105 weeks</time_frame>
        <population>All Treated Population. The efficacy outputs were presented according to planned study treatment. One participant in Part 2A was planned for 0.01mg, but received 0.003mg at first dose in error. One participant in Part 2A was planned for 0.003mg, but received 0.3mg at first dose in error. Hence, 'N' for the 'Part 2A: GSK3174998 0.01 mg/kg+Pembrolizumab 200 mg' arm is greater than that for the Participant Flow.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Objective Response Rate (ORR)</title>
          <description>ORR is defined as the percentage of participants achieving a confirmed CR or PR as the BOR, as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.</description>
          <population>All Treated Population. The efficacy outputs were presented according to planned study treatment. One participant in Part 2A was planned for 0.01mg, but received 0.003mg at first dose in error. One participant in Part 2A was planned for 0.003mg, but received 0.3mg at first dose in error. Hence, 'N' for the 'Part 2A: GSK3174998 0.01 mg/kg+Pembrolizumab 200 mg' arm is greater than that for the Participant Flow.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: Objective Response Rate (ORR)</title>
        <description>ORR is defined as the percentage of participants achieving a confirmed CR or PR as the BOR, as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.</description>
        <time_frame>Up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Objective Response Rate (ORR)</title>
          <description>ORR is defined as the percentage of participants achieving a confirmed CR or PR as the BOR, as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.</description>
          <population>All Treated Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Disease Control Rate (DCR)</title>
        <description>DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus stable disease (SD) &gt;=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.</description>
        <time_frame>Up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Disease Control Rate (DCR)</title>
          <description>DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus stable disease (SD) &gt;=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.</description>
          <population>All Treated Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: Disease Control Rate (DCR)</title>
        <description>DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus SD &gt;=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.</description>
        <time_frame>Up to maximum 105 weeks</time_frame>
        <population>All Treated Population. The efficacy outputs were presented according to planned study treatment. One participant in Part 2A was planned for 0.01mg, but received 0.003mg at first dose in error. One participant in Part 2A was planned for 0.003mg, but received 0.3mg at first dose in error. Hence, 'N' for the 'Part 2A: GSK3174998 0.01 mg/kg+Pembrolizumab 200 mg' arm is greater than that for the Participant Flow.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Disease Control Rate (DCR)</title>
          <description>DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus SD &gt;=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.</description>
          <population>All Treated Population. The efficacy outputs were presented according to planned study treatment. One participant in Part 2A was planned for 0.01mg, but received 0.003mg at first dose in error. One participant in Part 2A was planned for 0.003mg, but received 0.3mg at first dose in error. Hence, 'N' for the 'Part 2A: GSK3174998 0.01 mg/kg+Pembrolizumab 200 mg' arm is greater than that for the Participant Flow.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="58"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: Disease Control Rate (DCR)</title>
        <description>DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus SD &gt;=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.</description>
        <time_frame>Up to maximum 33 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Disease Control Rate (DCR)</title>
          <description>DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus SD &gt;=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 millimeter. PR: &gt;=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.</description>
          <population>All Treated Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points</title>
        <description>Blood samples for pharmacokinetic (PK) analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.</description>
        <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion</time_frame>
        <population>Pharmacokinetic Population consisted of all participants from the All Treated Population for whom a PK sample was obtained and analyzed. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points</title>
          <description>Blood samples for pharmacokinetic (PK) analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.</description>
          <population>Pharmacokinetic Population consisted of all participants from the All Treated Population for whom a PK sample was obtained and analyzed. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, predose, n=1,1,8,10,10,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                    <measurement group_id="O4" value="0.001" spread="0.0033"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                    <measurement group_id="O7" value="0.000" spread="0.0000"/>
                    <measurement group_id="O8" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 30minutes after EOI, n=1,1,8,10,10,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.044" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.181" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.893" spread="0.3505"/>
                    <measurement group_id="O4" value="2.958" spread="1.1359"/>
                    <measurement group_id="O5" value="6.091" spread="1.6075"/>
                    <measurement group_id="O6" value="23.224" spread="5.2813"/>
                    <measurement group_id="O7" value="77.500" spread="17.8619"/>
                    <measurement group_id="O8" value="277.615" spread="30.9564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 4hour after EOI, n=1,1,8,10,9,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.140" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.809" spread="0.3205"/>
                    <measurement group_id="O4" value="2.668" spread="1.0513"/>
                    <measurement group_id="O5" value="5.615" spread="1.3647"/>
                    <measurement group_id="O6" value="21.533" spread="5.5070"/>
                    <measurement group_id="O7" value="70.603" spread="15.1388"/>
                    <measurement group_id="O8" value="243.701" spread="42.5698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 24hour after EOI, n=1,1,6,10,9,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.083" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.564" spread="0.2508"/>
                    <measurement group_id="O4" value="2.080" spread="0.9446"/>
                    <measurement group_id="O5" value="4.954" spread="1.2600"/>
                    <measurement group_id="O6" value="17.645" spread="3.8210"/>
                    <measurement group_id="O7" value="59.143" spread="12.1864"/>
                    <measurement group_id="O8" value="191.862" spread="35.7293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=1,1,8,10,10,3,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.122" spread="0.0926"/>
                    <measurement group_id="O4" value="0.678" spread="0.4251"/>
                    <measurement group_id="O5" value="1.932" spread="0.3732"/>
                    <measurement group_id="O6" value="9.675" spread="2.9619"/>
                    <measurement group_id="O7" value="32.974" spread="8.4840"/>
                    <measurement group_id="O8" value="108.278" spread="44.5563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, n=1,1,8,9,10,3,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.022" spread="0.0412"/>
                    <measurement group_id="O4" value="0.190" spread="0.1577"/>
                    <measurement group_id="O5" value="1.205" spread="0.2799"/>
                    <measurement group_id="O6" value="5.303" spread="1.9430"/>
                    <measurement group_id="O7" value="21.705" spread="6.4334"/>
                    <measurement group_id="O8" value="80.909" spread="27.3394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22, predose, n=1,1,8,10,10,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.003" spread="0.0087"/>
                    <measurement group_id="O4" value="0.026" spread="0.0529"/>
                    <measurement group_id="O5" value="0.605" spread="0.2412"/>
                    <measurement group_id="O6" value="2.826" spread="2.1396"/>
                    <measurement group_id="O7" value="15.185" spread="4.1187"/>
                    <measurement group_id="O8" value="58.537" spread="17.2736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22, 30minutes after EOI, n=1,1,8,10,10,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.043" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.174" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.619" spread="0.2229"/>
                    <measurement group_id="O4" value="2.579" spread="0.4762"/>
                    <measurement group_id="O5" value="7.256" spread="1.8199"/>
                    <measurement group_id="O6" value="25.859" spread="9.2995"/>
                    <measurement group_id="O7" value="81.115" spread="32.5472"/>
                    <measurement group_id="O8" value="321.132" spread="40.4375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22, 4hour after EOI, n=1,1,8,10,9,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.149" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.523" spread="0.1963"/>
                    <measurement group_id="O4" value="2.301" spread="0.4088"/>
                    <measurement group_id="O5" value="6.519" spread="1.5717"/>
                    <measurement group_id="O6" value="22.905" spread="9.6502"/>
                    <measurement group_id="O7" value="82.690" spread="18.1793"/>
                    <measurement group_id="O8" value="306.585" spread="31.7702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22, 24hour after EOI, n=1,0,6,9,9,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.319" spread="0.1676"/>
                    <measurement group_id="O4" value="1.711" spread="0.4435"/>
                    <measurement group_id="O5" value="4.933" spread="0.8727"/>
                    <measurement group_id="O6" value="17.869" spread="9.3910"/>
                    <measurement group_id="O7" value="72.801" spread="17.5925"/>
                    <measurement group_id="O8" value="260.830" spread="44.1526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, n=0,1,8,10,10,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.037" spread="0.0663"/>
                    <measurement group_id="O4" value="0.380" spread="0.2882"/>
                    <measurement group_id="O5" value="2.243" spread="0.8667"/>
                    <measurement group_id="O6" value="8.654" spread="5.9929"/>
                    <measurement group_id="O7" value="42.013" spread="13.3448"/>
                    <measurement group_id="O8" value="153.655" spread="37.5871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36, n=0,1,7,9,9,4,6,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.013" spread="0.0313"/>
                    <measurement group_id="O4" value="0.115" spread="0.1114"/>
                    <measurement group_id="O5" value="1.227" spread="0.4101"/>
                    <measurement group_id="O6" value="6.428" spread="4.5933"/>
                    <measurement group_id="O7" value="31.093" spread="10.5909"/>
                    <measurement group_id="O8" value="111.545" spread="22.8298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43, predose, n=0,1,6,8,9,4,5,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.003" spread="0.0064"/>
                    <measurement group_id="O4" value="0.023" spread="0.0355"/>
                    <measurement group_id="O5" value="0.832" spread="0.5269"/>
                    <measurement group_id="O6" value="4.789" spread="3.2591"/>
                    <measurement group_id="O7" value="21.658" spread="8.9413"/>
                    <measurement group_id="O8" value="82.723" spread="26.1829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day43, 30minutes after EOI, n=0,1,6,7,9,3,5,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.267" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.547" spread="0.5929"/>
                    <measurement group_id="O4" value="2.130" spread="1.4403"/>
                    <measurement group_id="O5" value="7.373" spread="2.3810"/>
                    <measurement group_id="O6" value="30.602" spread="0.6521"/>
                    <measurement group_id="O7" value="95.775" spread="22.9300"/>
                    <measurement group_id="O8" value="302.882" spread="3.7341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64, predose, n=0,1,5,5,7,4,4,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.023" spread="0.0520"/>
                    <measurement group_id="O4" value="0.014" spread="0.0206"/>
                    <measurement group_id="O5" value="1.097" spread="0.4744"/>
                    <measurement group_id="O6" value="5.747" spread="3.8915"/>
                    <measurement group_id="O7" value="23.922" spread="9.6447"/>
                    <measurement group_id="O8" value="76.602" spread="27.6046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day64, 30minutes after EOI, n=0,0,5,5,7,4,4,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.339" spread="0.4499"/>
                    <measurement group_id="O4" value="1.154" spread="1.2985"/>
                    <measurement group_id="O5" value="7.952" spread="2.7538"/>
                    <measurement group_id="O6" value="21.941" spread="15.0801"/>
                    <measurement group_id="O7" value="98.410" spread="19.0269"/>
                    <measurement group_id="O8" value="312.277" spread="61.0388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85, predose, n=0,0,1,4,3,2,2,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="0.023" spread="0.0315"/>
                    <measurement group_id="O5" value="1.227" spread="0.7462"/>
                    <measurement group_id="O6" value="8.518" spread="0.6700"/>
                    <measurement group_id="O7" value="22.635" spread="3.1816"/>
                    <measurement group_id="O8" value="83.090" spread="31.8311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day85, 30minutes after EOI, n=0,0,1,4,3,2,2,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="1.246" spread="1.3975"/>
                    <measurement group_id="O5" value="9.421" spread="1.8598"/>
                    <measurement group_id="O6" value="32.824" spread="0.4611"/>
                    <measurement group_id="O7" value="82.402" spread="18.5192"/>
                    <measurement group_id="O8" value="294.788" spread="15.9947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day106, predose, n=0,0,1,1,2,2,1,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O5" value="1.323" spread="0.2234"/>
                    <measurement group_id="O6" value="8.497" spread="0.5922"/>
                    <measurement group_id="O7" value="19.047" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O8" value="94.359" spread="11.4639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day106, 30minutes after EOI, n=0,0,0,1,3,2,1,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1.591" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O5" value="8.377" spread="0.3270"/>
                    <measurement group_id="O6" value="33.406" spread="6.3673"/>
                    <measurement group_id="O7" value="79.852" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O8" value="307.222" spread="3.5048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points</title>
        <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.</description>
        <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points</title>
          <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, predose, n=4,5,9,10,11,11,12,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                    <measurement group_id="O4" value="0.000" spread="0.0000"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.928" spread="3.0764"/>
                    <measurement group_id="O7" value="0.000" spread="0.0000"/>
                    <measurement group_id="O8" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 30minutes after EOI, n=4,5,9,10,11,11,12,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051" spread="0.0212"/>
                    <measurement group_id="O2" value="0.235" spread="0.0971"/>
                    <measurement group_id="O3" value="0.833" spread="0.5313"/>
                    <measurement group_id="O4" value="2.088" spread="0.8049"/>
                    <measurement group_id="O5" value="6.542" spread="2.1648"/>
                    <measurement group_id="O6" value="25.623" spread="6.4576"/>
                    <measurement group_id="O7" value="70.550" spread="16.4984"/>
                    <measurement group_id="O8" value="193.082" spread="30.6483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 4hour after EOI, n=4,5,9,10,11,11,12,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" spread="0.0263"/>
                    <measurement group_id="O2" value="0.215" spread="0.0396"/>
                    <measurement group_id="O3" value="0.762" spread="0.4730"/>
                    <measurement group_id="O4" value="2.160" spread="1.0232"/>
                    <measurement group_id="O5" value="5.819" spread="1.6015"/>
                    <measurement group_id="O6" value="23.367" spread="4.5233"/>
                    <measurement group_id="O7" value="66.831" spread="17.5167"/>
                    <measurement group_id="O8" value="178.023" spread="20.6597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 24hour after EOI, n=4,5,9,10,11,11,12,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.0125"/>
                    <measurement group_id="O2" value="0.112" spread="0.0599"/>
                    <measurement group_id="O3" value="0.578" spread="0.4049"/>
                    <measurement group_id="O4" value="1.644" spread="0.7086"/>
                    <measurement group_id="O5" value="5.084" spread="1.7161"/>
                    <measurement group_id="O6" value="19.398" spread="5.6732"/>
                    <measurement group_id="O7" value="55.782" spread="13.0007"/>
                    <measurement group_id="O8" value="140.747" spread="9.5100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=4,5,10,11,14,11,12,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.428" spread="0.9836"/>
                    <measurement group_id="O4" value="0.592" spread="0.3233"/>
                    <measurement group_id="O5" value="2.203" spread="0.7619"/>
                    <measurement group_id="O6" value="12.151" spread="8.5380"/>
                    <measurement group_id="O7" value="30.442" spread="8.6063"/>
                    <measurement group_id="O8" value="71.830" spread="14.1731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=4,4,10,10,12,11,12,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.257" spread="0.7547"/>
                    <measurement group_id="O4" value="0.200" spread="0.1821"/>
                    <measurement group_id="O5" value="1.357" spread="0.7574"/>
                    <measurement group_id="O6" value="8.458" spread="8.3133"/>
                    <measurement group_id="O7" value="22.050" spread="6.8631"/>
                    <measurement group_id="O8" value="50.342" spread="12.5709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22, predose, n=3,2,10,10,12,10,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.106" spread="0.3359"/>
                    <measurement group_id="O4" value="0.080" spread="0.0880"/>
                    <measurement group_id="O5" value="0.626" spread="0.3716"/>
                    <measurement group_id="O6" value="6.912" spread="7.0973"/>
                    <measurement group_id="O7" value="16.354" spread="5.5789"/>
                    <measurement group_id="O8" value="31.882" spread="12.4466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22, 30minutes after EOI, n=3,2,10,10,12,9,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" spread="0.0350"/>
                    <measurement group_id="O2" value="0.879" spread="0.8898"/>
                    <measurement group_id="O3" value="0.754" spread="0.4533"/>
                    <measurement group_id="O4" value="2.343" spread="0.5196"/>
                    <measurement group_id="O5" value="7.496" spread="2.7519"/>
                    <measurement group_id="O6" value="30.238" spread="4.8782"/>
                    <measurement group_id="O7" value="85.882" spread="16.2709"/>
                    <measurement group_id="O8" value="222.118" spread="45.7084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22, 4hour after EOI, n=3,2,9,10,12,9,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.0406"/>
                    <measurement group_id="O2" value="0.682" spread="0.6743"/>
                    <measurement group_id="O3" value="0.704" spread="0.4011"/>
                    <measurement group_id="O4" value="2.203" spread="0.4515"/>
                    <measurement group_id="O5" value="6.938" spread="2.6934"/>
                    <measurement group_id="O6" value="27.273" spread="6.0059"/>
                    <measurement group_id="O7" value="82.796" spread="16.8542"/>
                    <measurement group_id="O8" value="205.085" spread="26.1667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22, 24hour after EOI, n=3,2,7,7,9,10,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.0188"/>
                    <measurement group_id="O2" value="0.365" spread="0.3729"/>
                    <measurement group_id="O3" value="0.628" spread="0.3755"/>
                    <measurement group_id="O4" value="1.702" spread="0.3438"/>
                    <measurement group_id="O5" value="6.015" spread="2.6501"/>
                    <measurement group_id="O6" value="21.631" spread="8.6914"/>
                    <measurement group_id="O7" value="69.978" spread="13.9446"/>
                    <measurement group_id="O8" value="164.798" spread="36.7704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, n=3,1,9,10,10,10,12,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.045" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.134" spread="0.2410"/>
                    <measurement group_id="O4" value="0.607" spread="0.3352"/>
                    <measurement group_id="O5" value="2.682" spread="1.5569"/>
                    <measurement group_id="O6" value="11.961" spread="5.5511"/>
                    <measurement group_id="O7" value="45.527" spread="14.7008"/>
                    <measurement group_id="O8" value="67.369" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36, n=3,2,8,8,8,10,11,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.019" spread="0.0404"/>
                    <measurement group_id="O4" value="0.243" spread="0.2081"/>
                    <measurement group_id="O5" value="1.994" spread="1.2562"/>
                    <measurement group_id="O6" value="9.146" spread="4.7873"/>
                    <measurement group_id="O7" value="33.671" spread="10.9055"/>
                    <measurement group_id="O8" value="106.605" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43, predose, n=3,3,7,7,8,9,12,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                    <measurement group_id="O4" value="0.071" spread="0.1213"/>
                    <measurement group_id="O5" value="0.950" spread="0.6068"/>
                    <measurement group_id="O6" value="7.207" spread="2.1852"/>
                    <measurement group_id="O7" value="24.578" spread="8.5351"/>
                    <measurement group_id="O8" value="74.088" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day43, 30minutes after EOI, n=3,3,7,7,8,8,12,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.071" spread="0.0156"/>
                    <measurement group_id="O2" value="0.229" spread="0.0379"/>
                    <measurement group_id="O3" value="0.496" spread="0.2657"/>
                    <measurement group_id="O4" value="1.922" spread="0.8919"/>
                    <measurement group_id="O5" value="7.639" spread="2.1641"/>
                    <measurement group_id="O6" value="28.433" spread="5.1446"/>
                    <measurement group_id="O7" value="94.463" spread="20.9570"/>
                    <measurement group_id="O8" value="377.078" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64, predose, n=1,3,2,6,4,8,10,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                    <measurement group_id="O4" value="0.067" spread="0.1145"/>
                    <measurement group_id="O5" value="0.706" spread="0.8655"/>
                    <measurement group_id="O6" value="8.349" spread="2.7499"/>
                    <measurement group_id="O7" value="32.716" spread="11.1159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day64, 30minutes after EOI, n=1,3,2,7,4,8,10,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.245" spread="0.0932"/>
                    <measurement group_id="O3" value="0.284" spread="0.4014"/>
                    <measurement group_id="O4" value="2.152" spread="1.3890"/>
                    <measurement group_id="O5" value="6.032" spread="3.2357"/>
                    <measurement group_id="O6" value="33.382" spread="5.0217"/>
                    <measurement group_id="O7" value="99.623" spread="25.2220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85, predose, n=0,3,0,5,5,7,8,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O4" value="0.115" spread="0.1528"/>
                    <measurement group_id="O5" value="0.938" spread="0.9332"/>
                    <measurement group_id="O6" value="10.323" spread="3.5051"/>
                    <measurement group_id="O7" value="35.166" spread="13.8402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day85, 30minutes after EOI, n=0,3,0,5,5,7,8,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.228" spread="0.0996"/>
                    <measurement group_id="O4" value="2.275" spread="1.2464"/>
                    <measurement group_id="O5" value="7.734" spread="2.5853"/>
                    <measurement group_id="O6" value="34.982" spread="6.5978"/>
                    <measurement group_id="O7" value="100.514" spread="26.7950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day106, predose, n=0,1,0,5,5,5,8,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="0.184" spread="0.1858"/>
                    <measurement group_id="O5" value="0.647" spread="0.8249"/>
                    <measurement group_id="O6" value="10.395" spread="5.5838"/>
                    <measurement group_id="O7" value="36.990" spread="16.0967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day106, 30minutes after EOI, n=0,1,0,5,4,5,8,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.269" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="2.477" spread="0.8254"/>
                    <measurement group_id="O5" value="8.218" spread="3.9343"/>
                    <measurement group_id="O6" value="33.183" spread="6.7012"/>
                    <measurement group_id="O7" value="108.103" spread="29.3324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points</title>
        <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.</description>
        <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points</title>
          <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, predose, n=7,5,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 30minutes after EOI, n=7,6,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.132" spread="2.6768"/>
                    <measurement group_id="O2" value="5.668" spread="1.1752"/>
                    <measurement group_id="O3" value="7.618" spread="0.6794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 4hour after EOI, n=7,6,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.229" spread="2.1553"/>
                    <measurement group_id="O2" value="5.383" spread="0.6932"/>
                    <measurement group_id="O3" value="6.638" spread="1.2259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 24hour after EOI, n=7,5,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" spread="1.7095"/>
                    <measurement group_id="O2" value="4.141" spread="1.0168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=8,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.972" spread="0.3899"/>
                    <measurement group_id="O2" value="2.062" spread="0.7993"/>
                    <measurement group_id="O3" value="2.501" spread="0.6042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=8,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" spread="0.3362"/>
                    <measurement group_id="O2" value="1.223" spread="0.5792"/>
                    <measurement group_id="O3" value="1.252" spread="0.3432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22, predose, n=8,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.401" spread="0.3015"/>
                    <measurement group_id="O2" value="0.646" spread="0.5756"/>
                    <measurement group_id="O3" value="0.444" spread="0.2856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22, 30minutes after EOI, n=8,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.805" spread="0.8298"/>
                    <measurement group_id="O2" value="6.259" spread="1.3552"/>
                    <measurement group_id="O3" value="7.226" spread="0.8588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22, 4hour after EOI, n=8,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.722" spread="1.5376"/>
                    <measurement group_id="O2" value="5.810" spread="1.4074"/>
                    <measurement group_id="O3" value="7.363" spread="1.0038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22, 24hour after EOI, n=4,2,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.531" spread="0.6357"/>
                    <measurement group_id="O2" value="2.070" spread="0.5224"/>
                    <measurement group_id="O3" value="5.850" spread="1.3604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, n=9,8,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.715" spread="0.8979"/>
                    <measurement group_id="O2" value="2.201" spread="1.4063"/>
                    <measurement group_id="O3" value="2.070" spread="0.9160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36, n=7,6,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.871" spread="0.7222"/>
                    <measurement group_id="O2" value="1.597" spread="1.2560"/>
                    <measurement group_id="O3" value="1.124" spread="0.5805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43, predose, n=8,4,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.442" spread="0.4862"/>
                    <measurement group_id="O2" value="1.045" spread="1.0289"/>
                    <measurement group_id="O3" value="0.570" spread="0.6971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day43, 30minutes after EOI, n=8,4,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.657" spread="1.1060"/>
                    <measurement group_id="O2" value="7.271" spread="2.0499"/>
                    <measurement group_id="O3" value="6.913" spread="2.3366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64, predose, n=4,3,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.726" spread="0.7935"/>
                    <measurement group_id="O2" value="1.520" spread="1.2083"/>
                    <measurement group_id="O3" value="0.663" spread="0.8153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day64, 30minutes after EOI, n=4,3,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.496" spread="1.7948"/>
                    <measurement group_id="O2" value="7.480" spread="2.0226"/>
                    <measurement group_id="O3" value="8.172" spread="0.5517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85, predose, n=2,3,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.976" spread="0.9973"/>
                    <measurement group_id="O2" value="1.631" spread="1.5426"/>
                    <measurement group_id="O3" value="0.711" spread="0.5122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day85, 30minutes after EOI, n=2,3,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.245" spread="0.2669"/>
                    <measurement group_id="O2" value="8.920" spread="2.4241"/>
                    <measurement group_id="O3" value="9.208" spread="1.3270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day106, predose, n=1,2,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.714" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.800" spread="1.0858"/>
                    <measurement group_id="O3" value="1.015" spread="0.6750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day106, 30minutes after EOI, n=2,2,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.933" spread="1.9969"/>
                    <measurement group_id="O2" value="6.324" spread="1.9856"/>
                    <measurement group_id="O3" value="8.673" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK3174998</title>
        <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
        <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles). There were not enough samples with concentrations above lower limit of quantification to allow calculation of AUC(0-tau) for 0.003mg and 0.01mg arms in Cycles 1 and 2. There was not enough PK sampling in Cycles 3,4 and 5 for all arms to allow calculation of AUC(0-tau).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK3174998</title>
          <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles). There were not enough samples with concentrations above lower limit of quantification to allow calculation of AUC(0-tau) for 0.003mg and 0.01mg arms in Cycles 1 and 2. There was not enough PK sampling in Cycles 3,4 and 5 for all arms to allow calculation of AUC(0-tau).</population>
          <units>Day*micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, n=0,0,6,10,9,3,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.9362" spread="56.6"/>
                    <measurement group_id="O4" value="11.272" spread="57.8"/>
                    <measurement group_id="O5" value="39.374" spread="17.5"/>
                    <measurement group_id="O6" value="175.09" spread="33.2"/>
                    <measurement group_id="O7" value="630.94" spread="23.7"/>
                    <measurement group_id="O8" value="2129.9" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, n=0,0,2,7,9,2,4,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.2804" spread="102.7"/>
                    <measurement group_id="O4" value="8.7296" spread="62.8"/>
                    <measurement group_id="O5" value="46.093" spread="30.7"/>
                    <measurement group_id="O6" value="255.78" spread="12.5"/>
                    <measurement group_id="O7" value="866.23" spread="33.5"/>
                    <measurement group_id="O8" value="2859.4" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: AUC(0-tau) of GSK3174998</title>
        <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
        <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles). There were not enough samples with concentrations above lower limit of quantification to allow calculation of AUC(0-tau) for 0.003mg and 0.01mg arms in Cycles 1 and 2. There was not enough PK sampling in Cycles 3,4 and 5 in all arms to allow calculation of AUC(0-tau).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: AUC(0-tau) of GSK3174998</title>
          <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles). There were not enough samples with concentrations above lower limit of quantification to allow calculation of AUC(0-tau) for 0.003mg and 0.01mg arms in Cycles 1 and 2. There was not enough PK sampling in Cycles 3,4 and 5 in all arms to allow calculation of AUC(0-tau).</population>
          <units>Day*micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, n=0,0,4,10,9,8,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.2333" spread="77.9"/>
                    <measurement group_id="O4" value="11.592" spread="42.4"/>
                    <measurement group_id="O5" value="40.936" spread="34.2"/>
                    <measurement group_id="O6" value="175.17" spread="32.6"/>
                    <measurement group_id="O7" value="605.22" spread="29.2"/>
                    <measurement group_id="O8" value="1465.8" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, n=0,0,2,6,7,8,12,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.0512" spread="64.9"/>
                    <measurement group_id="O4" value="10.862" spread="44.0"/>
                    <measurement group_id="O5" value="52.517" spread="78.9"/>
                    <measurement group_id="O6" value="271.67" spread="30.0"/>
                    <measurement group_id="O7" value="862.97" spread="30.8"/>
                    <measurement group_id="O8" value="2801.8" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: AUC(0-tau) of GSK3174998</title>
        <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
        <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles). There were not enough samples with concentrations above lower limit of quantification to allow calculation of AUC(0-tau) for 0.003mg and 0.01mg arms in Cycles 1 and 2. There was not enough PK sampling in Cycles 3,4 and 5 in all arms to allow calculation of AUC(0-tau).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: AUC(0-tau) of GSK3174998</title>
          <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles). There were not enough samples with concentrations above lower limit of quantification to allow calculation of AUC(0-tau) for 0.003mg and 0.01mg arms in Cycles 1 and 2. There was not enough PK sampling in Cycles 3,4 and 5 in all arms to allow calculation of AUC(0-tau).</population>
          <units>Day*micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, n=7,6,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.781" spread="9.6"/>
                    <measurement group_id="O2" value="38.171" spread="43.4"/>
                    <measurement group_id="O3" value="46.544" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, n=7,4,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.504" spread="31.6"/>
                    <measurement group_id="O2" value="41.838" spread="96.8"/>
                    <measurement group_id="O3" value="33.502" spread="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998</title>
        <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
        <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998</title>
          <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, Cycle 1, n=1,1,8,10,10,4,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04440" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.1814" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.8408" spread="43.1"/>
                    <measurement group_id="O4" value="2.808" spread="35.5"/>
                    <measurement group_id="O5" value="6.002" spread="24.0"/>
                    <measurement group_id="O6" value="22.70" spread="26.0"/>
                    <measurement group_id="O7" value="75.81" spread="22.9"/>
                    <measurement group_id="O8" value="276.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 2, n=1,1,8,10,10,4,6,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04280" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.1737" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.5816" spread="40.9"/>
                    <measurement group_id="O4" value="2.539" spread="20.4"/>
                    <measurement group_id="O5" value="7.096" spread="25.8"/>
                    <measurement group_id="O6" value="24.13" spread="49.4"/>
                    <measurement group_id="O7" value="90.26" spread="21.9"/>
                    <measurement group_id="O8" value="320.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 3, n=0,1,6,7,9,3,5,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.2671" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.2532" spread="369.2"/>
                    <measurement group_id="O4" value="1.355" spread="206.1"/>
                    <measurement group_id="O5" value="7.011" spread="35.7"/>
                    <measurement group_id="O6" value="30.60" spread="2.1"/>
                    <measurement group_id="O7" value="93.67" spread="23.7"/>
                    <measurement group_id="O8" value="302.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 4, n=0,0,3,4,7,4,4,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.3112" spread="395.0"/>
                    <measurement group_id="O4" value="0.5338" spread="1632.6"/>
                    <measurement group_id="O5" value="7.573" spread="34.5"/>
                    <measurement group_id="O6" value="8.117" spread="2535.5"/>
                    <measurement group_id="O7" value="97.02" spread="19.7"/>
                    <measurement group_id="O8" value="309.3" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 5, n=0,0,0,3,3,2,2,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1.024" spread="264.9"/>
                    <measurement group_id="O5" value="9.292" spread="20.9"/>
                    <measurement group_id="O6" value="32.82" spread="1.4"/>
                    <measurement group_id="O7" value="81.35" spread="23.0"/>
                    <measurement group_id="O8" value="294.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 1, n=0,0,1,4,10,3,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.02450" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="0.04138" spread="139.4"/>
                    <measurement group_id="O5" value="0.5417" spread="62.6"/>
                    <measurement group_id="O6" value="3.626" spread="35.4"/>
                    <measurement group_id="O7" value="14.73" spread="26.9"/>
                    <measurement group_id="O8" value="56.29" spread="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 2, n=0,0,1,3,9,3,5,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.01570" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="0.05811" spread="50.0"/>
                    <measurement group_id="O5" value="0.6702" spread="86.3"/>
                    <measurement group_id="O6" value="6.353" spread="12.3"/>
                    <measurement group_id="O7" value="19.92" spread="51.3"/>
                    <measurement group_id="O8" value="79.63" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 3, n=0,0,1,2,7,3,4,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.1162" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="0.03436" spread="39.2"/>
                    <measurement group_id="O5" value="0.9979" spread="52.7"/>
                    <measurement group_id="O6" value="7.633" spread="10.9"/>
                    <measurement group_id="O7" value="22.57" spread="40.3"/>
                    <measurement group_id="O8" value="72.89" spread="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 4, n=0,0,0,2,3,2,2,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.04153" spread="75.0"/>
                    <measurement group_id="O5" value="1.053" spread="81.8"/>
                    <measurement group_id="O6" value="8.504" spread="7.9"/>
                    <measurement group_id="O7" value="22.52" spread="14.2"/>
                    <measurement group_id="O8" value="78.37" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 5, n=0,0,0,0,2,2,1,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1.313" spread="17.1"/>
                    <measurement group_id="O6" value="8.486" spread="7.0"/>
                    <measurement group_id="O7" value="19.05" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O8" value="94.01" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: Cmax and Cmin of GSK3174998</title>
        <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
        <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Cmax and Cmin of GSK3174998</title>
          <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, Cycle 1, n=4,5,9,10,11,9,12,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05321" spread="37.3"/>
                    <measurement group_id="O2" value="0.2505" spread="23.6"/>
                    <measurement group_id="O3" value="0.6748" spread="95.1"/>
                    <measurement group_id="O4" value="2.446" spread="23.4"/>
                    <measurement group_id="O5" value="6.345" spread="30.8"/>
                    <measurement group_id="O6" value="23.84" spread="18.9"/>
                    <measurement group_id="O7" value="71.37" spread="24.1"/>
                    <measurement group_id="O8" value="191.3" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 2, n=3,1,9,9,12,9,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07490" spread="43.7"/>
                    <measurement group_id="O2" value="0.2496" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="0.7805" spread="44.6"/>
                    <measurement group_id="O4" value="2.419" spread="17.8"/>
                    <measurement group_id="O5" value="7.129" spread="37.2"/>
                    <measurement group_id="O6" value="29.87" spread="16.8"/>
                    <measurement group_id="O7" value="86.21" spread="20.4"/>
                    <measurement group_id="O8" value="220.0" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 3, n=3,3,6,7,8,8,12,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06961" spread="23.1"/>
                    <measurement group_id="O2" value="0.2269" spread="16.0"/>
                    <measurement group_id="O3" value="0.5577" spread="31.4"/>
                    <measurement group_id="O4" value="1.614" spread="90.5"/>
                    <measurement group_id="O5" value="7.373" spread="29.2"/>
                    <measurement group_id="O6" value="28.02" spread="18.4"/>
                    <measurement group_id="O7" value="92.25" spread="23.4"/>
                    <measurement group_id="O8" value="377.1" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 4, n=1,3,1,7,4,8,10,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06740" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.2328" spread="0.2328"/>
                    <measurement group_id="O3" value="0.5677" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="1.565" spread="133.4"/>
                    <measurement group_id="O5" value="4.898" spread="107.0"/>
                    <measurement group_id="O6" value="33.06" spread="14.7"/>
                    <measurement group_id="O7" value="96.86" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 5, n=0,3,0,5,5,7,8,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.2095" spread="56.6"/>
                    <measurement group_id="O4" value="1.664" spread="161.3"/>
                    <measurement group_id="O5" value="7.427" spread="31.8"/>
                    <measurement group_id="O6" value="34.37" spread="21.3"/>
                    <measurement group_id="O7" value="97.28" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 1, n=0,0,1,6,12,9,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.062" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="0.1120" spread="77.4"/>
                    <measurement group_id="O5" value="0.5031" spread="90.6"/>
                    <measurement group_id="O6" value="5.971" spread="77.9"/>
                    <measurement group_id="O7" value="15.04" spread="52.1"/>
                    <measurement group_id="O8" value="30.32" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 2, n=0,0,0,2,8,9,12,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.2482" spread="5.2"/>
                    <measurement group_id="O5" value="0.6783" spread="161.3"/>
                    <measurement group_id="O6" value="6.887" spread="33.9"/>
                    <measurement group_id="O7" value="22.94" spread="43.8"/>
                    <measurement group_id="O8" value="74.09" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 3, n=0,0,0,3,4,8,10,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.09191" spread="148.0"/>
                    <measurement group_id="O5" value="0.2505" spread="667.3"/>
                    <measurement group_id="O6" value="7.900" spread="38.3"/>
                    <measurement group_id="O7" value="30.77" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 4, n=0,0,0,3,5,7,8,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.1536" spread="95.4"/>
                    <measurement group_id="O5" value="0.4313" spread="383.9"/>
                    <measurement group_id="O6" value="9.882" spread="31.8"/>
                    <measurement group_id="O7" value="32.44" spread="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 5, n=0,0,0,3,4,5,8,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.2912" spread="42.9"/>
                    <measurement group_id="O5" value="0.3995" spread="407.8"/>
                    <measurement group_id="O6" value="9.244" spread="59.5"/>
                    <measurement group_id="O7" value="33.69" spread="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: Cmax and Cmin of GSK3174998</title>
        <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
        <time_frame>Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Cmax and Cmin of GSK3174998</title>
          <description>Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, Cycle 1, n=6,6,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.921" spread="19.1"/>
                    <measurement group_id="O2" value="5.717" spread="17.4"/>
                    <measurement group_id="O3" value="7.596" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 2, n=8,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.114" spread="19.3"/>
                    <measurement group_id="O2" value="6.139" spread="21.9"/>
                    <measurement group_id="O3" value="7.398" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 3, n=8,4,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.574" spread="17.3"/>
                    <measurement group_id="O2" value="7.066" spread="27.9"/>
                    <measurement group_id="O3" value="6.712" spread="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 4, n=4,3,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.352" spread="22.5"/>
                    <measurement group_id="O2" value="7.296" spread="28.1"/>
                    <measurement group_id="O3" value="8.162" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Cycle 5, n=2,3,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.24" spread="2.6"/>
                    <measurement group_id="O2" value="8.684" spread="29.5"/>
                    <measurement group_id="O3" value="9.160" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 1, n=7,5,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3781" spread="81.6"/>
                    <measurement group_id="O2" value="0.7925" spread="68.4"/>
                    <measurement group_id="O3" value="0.3823" spread="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 2, n=7,3,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3082" spread="187.9"/>
                    <measurement group_id="O2" value="1.092" spread="123.1"/>
                    <measurement group_id="O3" value="0.2857" spread="552.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 3, n=3,3,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7464" spread="117.5"/>
                    <measurement group_id="O2" value="0.9898" spread="225.3"/>
                    <measurement group_id="O3" value="0.3280" spread="577.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 4, n=2,3,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6753" spread="207.0"/>
                    <measurement group_id="O2" value="0.6852" spread="947.6"/>
                    <measurement group_id="O3" value="0.6114" spread="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Cycle 5, n=1,2,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.714" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="0.2250" spread="4329.5"/>
                    <measurement group_id="O3" value="0.8955" spread="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points</title>
        <description>Blood samples for PK analysis of pembrolizumab were collected on Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion (EOPI); anytime on Days 8,15; Pre-dose on Days 22, 64, 106.</description>
        <time_frame>Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22, 64, 106</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points</title>
          <description>Blood samples for PK analysis of pembrolizumab were collected on Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion (EOPI); anytime on Days 8,15; Pre-dose on Days 22, 64, 106.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, predose, n=5,4,7,9,10,7,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="4.414" spread="11.6791"/>
                    <measurement group_id="O4" value="0.000" spread="0.0000"/>
                    <measurement group_id="O5" value="0.404" spread="1.2776"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                    <measurement group_id="O7" value="0.008" spread="0.0284"/>
                    <measurement group_id="O8" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 30minutes after EOPI, n=5,1,8,6,8,7,10,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.860" spread="28.8970"/>
                    <measurement group_id="O2" value="41.000" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="72.588" spread="38.0995"/>
                    <measurement group_id="O4" value="62.983" spread="30.3605"/>
                    <measurement group_id="O5" value="59.175" spread="24.1666"/>
                    <measurement group_id="O6" value="75.857" spread="21.3825"/>
                    <measurement group_id="O7" value="66.100" spread="15.2560"/>
                    <measurement group_id="O8" value="65.100" spread="15.6721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 24hour after EOPI, n=5,4,10,8,10,12,12,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.140" spread="10.7050"/>
                    <measurement group_id="O2" value="56.675" spread="17.3734"/>
                    <measurement group_id="O3" value="65.230" spread="21.4209"/>
                    <measurement group_id="O4" value="50.463" spread="19.1378"/>
                    <measurement group_id="O5" value="53.810" spread="32.8301"/>
                    <measurement group_id="O6" value="54.442" spread="17.3552"/>
                    <measurement group_id="O7" value="51.842" spread="16.3551"/>
                    <measurement group_id="O8" value="48.900" spread="15.1969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=5,4,10,11,14,12,12,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.340" spread="6.0719"/>
                    <measurement group_id="O2" value="29.600" spread="8.7882"/>
                    <measurement group_id="O3" value="33.850" spread="13.1268"/>
                    <measurement group_id="O4" value="27.618" spread="10.6709"/>
                    <measurement group_id="O5" value="30.757" spread="13.6721"/>
                    <measurement group_id="O6" value="35.600" spread="16.0615"/>
                    <measurement group_id="O7" value="32.792" spread="9.0537"/>
                    <measurement group_id="O8" value="34.025" spread="11.7196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=5,4,10,9,13,12,11,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.560" spread="4.1531"/>
                    <measurement group_id="O2" value="21.575" spread="8.7332"/>
                    <measurement group_id="O3" value="25.020" spread="10.7905"/>
                    <measurement group_id="O4" value="21.611" spread="7.3849"/>
                    <measurement group_id="O5" value="21.369" spread="10.9198"/>
                    <measurement group_id="O6" value="26.525" spread="16.4784"/>
                    <measurement group_id="O7" value="25.773" spread="5.3967"/>
                    <measurement group_id="O8" value="25.175" spread="11.0852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22, predose, n=5,3,9,10,11,11,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.192" spread="3.4140"/>
                    <measurement group_id="O2" value="12.333" spread="1.5177"/>
                    <measurement group_id="O3" value="17.610" spread="9.7207"/>
                    <measurement group_id="O4" value="17.892" spread="6.6164"/>
                    <measurement group_id="O5" value="18.245" spread="12.8696"/>
                    <measurement group_id="O6" value="19.336" spread="13.4661"/>
                    <measurement group_id="O7" value="18.067" spread="5.2824"/>
                    <measurement group_id="O8" value="18.567" spread="10.6679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64, predose, n=3,3,2,6,5,8,10,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.433" spread="6.7678"/>
                    <measurement group_id="O2" value="30.133" spread="8.5008"/>
                    <measurement group_id="O3" value="38.550" spread="13.9300"/>
                    <measurement group_id="O4" value="26.560" spread="14.4486"/>
                    <measurement group_id="O5" value="30.720" spread="8.1940"/>
                    <measurement group_id="O6" value="37.000" spread="14.0108"/>
                    <measurement group_id="O7" value="33.640" spread="11.8732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106, predose, n=1,1,0,6,5,5,8,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.500" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="28.100" spread="NA">Standard deviation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="40.150" spread="14.0395"/>
                    <measurement group_id="O5" value="45.420" spread="20.7985"/>
                    <measurement group_id="O6" value="41.400" spread="17.4579"/>
                    <measurement group_id="O7" value="42.850" spread="17.0662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points</title>
        <description>Blood samples for PK analysis of pembrolizumab were collected on Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22, 64, 106.</description>
        <time_frame>Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22, 64, 106</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points</title>
          <description>Blood samples for PK analysis of pembrolizumab were collected on Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22, 64, 106.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, predose, n=8,8,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.341" spread="5.7855"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="11.940" spread="7.3057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 30minutes after EOPI, n=8,6,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.650" spread="12.5860"/>
                    <measurement group_id="O2" value="66.600" spread="15.4104"/>
                    <measurement group_id="O3" value="68.633" spread="7.2473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 24hour after EOPI, n=8,5,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.800" spread="12.7711"/>
                    <measurement group_id="O2" value="49.960" spread="7.3228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=9,8,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.178" spread="10.0888"/>
                    <measurement group_id="O2" value="26.125" spread="7.6333"/>
                    <measurement group_id="O3" value="33.800" spread="7.5931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=9,7,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.800" spread="8.8255"/>
                    <measurement group_id="O2" value="19.343" spread="7.3968"/>
                    <measurement group_id="O3" value="25.280" spread="5.7712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22, predose, n=9,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.458" spread="6.4173"/>
                    <measurement group_id="O2" value="15.180" spread="6.4652"/>
                    <measurement group_id="O3" value="18.775" spread="4.7479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64, predose, n=4,3,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.775" spread="8.2754"/>
                    <measurement group_id="O2" value="43.900" spread="12.1520"/>
                    <measurement group_id="O3" value="22.800" spread="6.0902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 106, predose, n=2,3,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.750" spread="10.6773"/>
                    <measurement group_id="O2" value="44.200" spread="24.5514"/>
                    <measurement group_id="O3" value="23.867" spread="10.1535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: AUC(0-tau) of Pembrolizumab</title>
        <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
        <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. There were not enough PK sampling in Cycles 3 and 5 to allow calculation of AUC (0-tau).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: AUC(0-tau) of Pembrolizumab</title>
          <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. There were not enough PK sampling in Cycles 3 and 5 to allow calculation of AUC (0-tau).</population>
          <units>Day*micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.11" spread="43.3"/>
                    <measurement group_id="O2" value="561.35" spread="34.2"/>
                    <measurement group_id="O3" value="616.43" spread="43.7"/>
                    <measurement group_id="O4" value="581.61" spread="34.1"/>
                    <measurement group_id="O5" value="528.06" spread="33.4"/>
                    <measurement group_id="O6" value="639.86" spread="44.8"/>
                    <measurement group_id="O7" value="657.22" spread="22.5"/>
                    <measurement group_id="O8" value="703.61" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: AUC(0-tau) of Pembrolizumab</title>
        <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
        <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. There were not enough PK sampling in Cycles 3 and 5 to allow calculation of AUC (0-tau).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: AUC(0-tau) of Pembrolizumab</title>
          <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. There were not enough PK sampling in Cycles 3 and 5 to allow calculation of AUC (0-tau).</population>
          <units>Day*micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470.80" spread="31.5"/>
                    <measurement group_id="O2" value="546.97" spread="29.1"/>
                    <measurement group_id="O3" value="487.40" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: Cmax of Pembrolizumab</title>
        <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
        <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. Post-dose samples were collected in Cycle 1 only and were not collected in Cycles 3 and 5 to calculate Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Cmax of Pembrolizumab</title>
          <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. Post-dose samples were collected in Cycle 1 only and were not collected in Cycles 3 and 5 to calculate Cmax.</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.83" spread="48.5"/>
                    <measurement group_id="O2" value="41.00" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O3" value="79.00" spread="34.8"/>
                    <measurement group_id="O4" value="57.00" spread="52.7"/>
                    <measurement group_id="O5" value="60.20" spread="36.2"/>
                    <measurement group_id="O6" value="72.73" spread="34.2"/>
                    <measurement group_id="O7" value="64.66" spread="22.0"/>
                    <measurement group_id="O8" value="63.65" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: Cmax of Pembrolizumab</title>
        <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
        <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. Post-dose samples were collected in Cycle 1 only and were not collected in Cycles 3 and 5 to calculate Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Cmax of Pembrolizumab</title>
          <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. Post-dose samples were collected in Cycle 1 only and were not collected in Cycles 3 and 5 to calculate Cmax.</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.03" spread="19.6"/>
                    <measurement group_id="O2" value="65.32" spread="21.1"/>
                    <measurement group_id="O3" value="64.60" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: Cmin of Pembrolizumab</title>
        <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
        <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Cmin of Pembrolizumab</title>
          <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, n=5,3,9,10,11,11,12,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.85" spread="26.8"/>
                    <measurement group_id="O2" value="12.27" spread="12.6"/>
                    <measurement group_id="O3" value="15.52" spread="56.6"/>
                    <measurement group_id="O4" value="16.70" spread="42.6"/>
                    <measurement group_id="O5" value="15.81" spread="54.5"/>
                    <measurement group_id="O6" value="16.86" spread="52.2"/>
                    <measurement group_id="O7" value="17.39" spread="29.6"/>
                    <measurement group_id="O8" value="16.78" spread="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, n=3,3,2,6,5,8,10,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.71" spread="32.7"/>
                    <measurement group_id="O2" value="29.40" spread="27.1"/>
                    <measurement group_id="O3" value="37.27" spread="38.3"/>
                    <measurement group_id="O4" value="22.06" spread="85.1"/>
                    <measurement group_id="O5" value="29.93" spread="25.3"/>
                    <measurement group_id="O6" value="34.41" spread="44.6"/>
                    <measurement group_id="O7" value="32.02" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5, n=1,1,0,6,5,5,8,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.50" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O2" value="28.10" spread="NA">Geometric coefficient of variation could not be calculated due to single participant</measurement>
                    <measurement group_id="O4" value="37.73" spread="42.2"/>
                    <measurement group_id="O5" value="41.02" spread="57.0"/>
                    <measurement group_id="O6" value="38.13" spread="49.7"/>
                    <measurement group_id="O7" value="39.38" spread="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: Cmin of Pembrolizumab</title>
        <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
        <time_frame>Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Cmin of Pembrolizumab</title>
          <description>Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, n=9,7,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.30" spread="45.9"/>
                    <measurement group_id="O2" value="13.88" spread="50.3"/>
                    <measurement group_id="O3" value="18.22" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, n=4,3,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.78" spread="34.2"/>
                    <measurement group_id="O2" value="42.86" spread="26.9"/>
                    <measurement group_id="O3" value="22.28" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5, n=2,3,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.52" spread="49.2"/>
                    <measurement group_id="O2" value="39.78" spread="61.3"/>
                    <measurement group_id="O3" value="22.52" spread="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Positive Antidrug Antibodies (ADAs) Against GSK3174998</title>
        <description>Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point determined during assay validation. Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.</description>
        <time_frame>Up to maximum 39 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3174998 0.003 mg/kg</title>
            <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3174998 0.01 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3174998 0.03 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3174998 0.1 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3174998 0.3 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK3174998 1.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK3174998 3.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK3174998 10.0 mg/kg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Positive Antidrug Antibodies (ADAs) Against GSK3174998</title>
          <description>Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point determined during assay validation. Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: Number of Participants With Positive ADAs Against GSK3174998</title>
        <description>Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.</description>
        <time_frame>Up to maximum 105 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Positive ADAs Against GSK3174998</title>
          <description>Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.</description>
          <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: Number of Participants With Positive ADAs Against GSK3174998</title>
        <description>Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.</description>
        <time_frame>Up to maximum 33 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Positive ADAs Against GSK3174998</title>
          <description>Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.</description>
          <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2A: Number of Participants With Positive ADAs Against Pembrolizumab</title>
        <description>Serum samples were collected for the determination of anti-pembrolizumab antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a pembrolizumab bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with pembrolizumab that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-pembrolizumab antibodies results at any visit during the study have been presented.</description>
        <time_frame>Up to maximum 105 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O2">
            <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O3">
            <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O4">
            <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O5">
            <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O6">
            <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O7">
            <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
          <group group_id="O8">
            <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
            <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2A: Number of Participants With Positive ADAs Against Pembrolizumab</title>
          <description>Serum samples were collected for the determination of anti-pembrolizumab antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a pembrolizumab bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with pembrolizumab that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-pembrolizumab antibodies results at any visit during the study have been presented.</description>
          <population>All Treated Population. Only those participants with data available at the indicated data points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2B: Number of Participants With Positive ADAs Against Pembrolizumab</title>
        <description>Serum samples were planned to be collected for the determination of anti-pembrolizumab antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps.</description>
        <time_frame>Up to maximum 33 weeks</time_frame>
        <population>All Treated Population. Data for this outcome measure was not collected as ADA samples were not collected in Part 2B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2B: Melanoma Cohort</title>
            <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O2">
            <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
            <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
          <group group_id="O3">
            <title>Part 2B: NSCLC Cohort</title>
            <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2B: Number of Participants With Positive ADAs Against Pembrolizumab</title>
          <description>Serum samples were planned to be collected for the determination of anti-pembrolizumab antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps.</description>
          <population>All Treated Population. Data for this outcome measure was not collected as ADA samples were not collected in Part 2B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B</time_frame>
      <desc>All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: GSK3174998 0.003 mg/kg</title>
          <description>Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: GSK3174998 0.01 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: GSK3174998 0.03 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: GSK3174998 0.1 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 1: GSK3174998 0.3 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="E6">
          <title>Part 1: GSK3174998 1.0 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="E7">
          <title>Part 1: GSK3174998 3.0 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="E8">
          <title>Part 1: GSK3174998 10.0 mg/kg</title>
          <description>Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.</description>
        </group>
        <group group_id="E9">
          <title>Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="E10">
          <title>Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="E11">
          <title>Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="E12">
          <title>Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="E13">
          <title>Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="E14">
          <title>Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="E15">
          <title>Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="E16">
          <title>Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg</title>
          <description>Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.</description>
        </group>
        <group group_id="E17">
          <title>Part 2B: Melanoma Cohort</title>
          <description>Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
        </group>
        <group group_id="E18">
          <title>Part 2B: Soft Tissue Sarcoma Cohort</title>
          <description>Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
        </group>
        <group group_id="E19">
          <title>Part 2B: NSCLC Cohort</title>
          <description>Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pituitary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Metastases to pituitary gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pharyngeal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hereditary non-polyposis colorectal cancer syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="6" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E13" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="11" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E13" events="6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E15" events="6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="6" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Post-traumatic headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vaginal ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Erythema annulare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Onycholysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

